Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-CD44 variant monoclonal antibodies - MaimoniDex RA

Drug Profile

Research programme: anti-CD44 variant monoclonal antibodies - MaimoniDex RA

Alternative Names: Anti-CD44 variant monoclonal antibodies research programme - Maimonidex RA; MD-101

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MaimoniDex RA
  • Class Monoclonal antibodies
  • Mechanism of Action CD44 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Israel (Injection, Injection)
  • 23 Sep 2005 MaimoniDex RA and Abmaxis have entered into an agreement to jointly develop a human monoclonal antibody for rheumatoid arthritis and other inflammatory diseases
  • 15 Jul 2005 Anti-CD44 variant monoclonal antibodies are available for partnering
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top